Mangiferin activates Nrf2 to attenuate cardiac fibrosis via redistributing glutaminolysis-derived glutamate

Proposed mechanism for mangiferin to restrain cardiac fibrosis. Mangiferin increases Nrf2 induction by promoting Keap1. As a result, mangiferin redistributes intracellular glutamate for the synthesis reduced glutathione (GSH), resultantly restraining cardiac myofibroblast activation by reducing glut...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmacological research 2020-07, Vol.157, p.104845-104845, Article 104845
Hauptverfasser: Song, Junna, Meng, Yunxia, Wang, Meng, Li, Lanzhu, Liu, Zhao, Zheng, Kaiyan, Wu, Lanfang, Liu, Baolin, Hou, Fangjie, Li, Aiying
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Proposed mechanism for mangiferin to restrain cardiac fibrosis. Mangiferin increases Nrf2 induction by promoting Keap1. As a result, mangiferin redistributes intracellular glutamate for the synthesis reduced glutathione (GSH), resultantly restraining cardiac myofibroblast activation by reducing glutamate availability for metabolic support. [Display omitted] •Mangiferin activates Nrf2 to attenuate cardiac fibrosis.•Glutaminolysis-derived glutamate is required for myofibroblast activation to support metabolism.•Nrf2 inhibits myofibroblast activation by redistributing glutamate for glutathione synthesis. Cardiac injury is followed by fibrosis, characterized by myofibroblast activation. Excessive deposition of extracellular matrix (ECM) impairs the plasticity of myocardium and results in myocardial systolic and diastolic dysfunction. Mangiferin is a xanthonoid derivative rich in plants mangoes and iris unguicularis, exhibiting the ability to ameliorate metabolic disorders. This study aims to investigate whether mangiferin attenuates cardiac fibrosis via redox regulation. The transverse aortic constriction (TAC) in mice induced cardiac fibrosis with impaired heart function. Oral administration of mangiferin (50 mg/kg, 4 weeks) inhibited myofibroblast activation with reduced formation of ECM. The impaired left ventricular contractive function was also improved by mangiferin. TGF-β1 stimulation increased glutaminolysis to fuel intracellular glutamate pool for the increased demands of nutrients to support cardiac myofibroblast activation. Mangiferin degraded Keap1 to promote Nrf2 protein accumulation by improving its stability, leading to Nrf2 activation. Nrf2 transcriptionally promotes the synthesis of antioxidant proteins. By activating Nrf2, mangiferin promoted the synthesis of glutathione (GSH) in cardiac fibroblasts, likely due to the consumption of glutaminolysis-derived glutamate as a source. Meanwhile, mangiferin promoted the exchange of intracellular glutamate for the import of extracellular cystine to support GSH generation. As a result of redistribution, the reduced glutamate availability failed to support myofibroblast activation. In support of this, the addition of extracellular glutamate or α-ketoglutarate diminished the inhibitory effects of mangiferin on cardiac myofibroblast proliferation and activation. Moreover, cardiac knockdown of Nrf2 attenuated the cardioprotective effects of mangiferin in mice subjected to TAC. In conclusion, we demonstrate
ISSN:1043-6618
1096-1186
DOI:10.1016/j.phrs.2020.104845